Etamsylate Doesn’t Change Blood Clotting Parameters at Standard Doses — Here’s What That Means
Etamsylate has been on pharmacy shelves since 1959. Doctors prescribe it for heavy menstrual bleeding. Veterinarians give it to dogs with hemorrhagic diarrhea. Surgeons use it when they’re worried about post-operative bleeding. The drug is available in dozens of countries under brand names like Dicynone and Hemosilate, and it’s generally considered safe.
Here’s the problem: nobody can agree on how it actually works.
What etamsylate is supposed to do
Etamsylate is a hemostatic agent, meaning it’s meant to help stop bleeding. Unlike tranexamic acid, which prevents existing clots from breaking down, etamsylate targets an earlier step. According to the textbook explanation, it activates platelets, makes capillary walls less fragile, and blocks the release of prostacyclin (a molecule that keeps blood vessels dilated and discourages clotting).
Some of this has been demonstrated in animal models. Rabbits given etamsylate showed shorter bleeding times. Rat studies found evidence of platelet activation and increased P-selectin expression. The mechanism looks plausible on paper.
But paper isn’t a patient.
The Munich study
A team at Ludwig Maximilian University of Munich recently published one of the most rigorous investigations into etamsylate’s actual effects on blood. They enrolled 30 client-owned dogs split into three groups: dogs heading into high-bleed-risk surgeries like liver biopsies, dogs actively bleeding from trauma or clotting disorders, and dogs with thrombocytopenia (platelet counts below 80 × 10⁹/L).
Each dog got a single IV dose of 12.5 mg/kg etamsylate. Blood was drawn before the injection and again 90 minutes after. The team ran full coagulation panels: CBC, prothrombin time, activated partial thromboplastin time, fibrinogen, and thromboelastography (TEG).
TEG is worth explaining because it’s central to why this study matters. Unlike standard clotting tests, TEG measures clot formation in real time inside a rotating cup. It tracks reaction time (R), how fast the clot strengthens (α angle), time to reach a target strength (K), maximum clot strength (MA), and whether the clot dissolves too quickly (LY30). MA in particular is driven mostly by platelet count and function, making it a reasonable proxy for primary hemostasis. If etamsylate genuinely activates platelets, MA should move.
It didn’t.
The results, or lack thereof
Nothing changed. Not the TEG parameters, not the platelet counts, not the fibrinogen, not PT or aPTT. Across all 30 dogs and all three subgroups, every measurement stayed within the same statistical range before and after the injection.
There were minor numerical shifts here and there. Platelet counts dropped about 10% on average, and PT inched up by roughly a second. But after applying the Holm-Bonferroni correction for multiple comparisons, those differences vanished. They were noise, not signal.
No adverse events were observed in any dog, which is itself a useful data point.
Why the disconnect with clinical evidence?
This is where it gets interesting. Some earlier clinical trials have reported that etamsylate does seem to help. A study of dogs with hemorrhagic diarrhea found that animals on etamsylate recovered normal stools faster (6.4 days versus 10.7 days) and lost less protein. In human medicine, the drug has been used for decades with the general impression that it works.
So patients appear to benefit, yet the drug produces no measurable change in the blood tests that should explain that benefit. How?
The most likely answer has to do with what TEG and standard lab tests can’t see. Etamsylate’s proposed effects on vascular endothelium, the inner lining of blood vessels, wouldn’t show up in a test tube. If the drug primarily reduces capillary fragility or promotes platelet adhesion to damaged vessel walls, you need the vessel wall present to measure it. TEG uses a plastic cup. There is no vessel wall.
There are other possibilities too. The dose might be too low. The 90-minute sampling window might miss peak activity. Earlier research found dose-dependent effects, and some clinical protocols give the drug four times daily for days, not as a single bolus. In vitro studies have shown that adding etamsylate directly to blood samples at high concentrations does change TEG readings, which suggests the drug isn’t inert. It just may not reach effective concentrations at the standard clinical dose.
What does this mean for clinical practice?
Nobody is saying throw the drug away. Etamsylate has a clean safety record across decades of use in both human and veterinary medicine. The Munich study found no adverse events, and other work has shown tolerability up to 200 mg/kg in dogs. That’s a wide margin above the standard 12.5 mg/kg dose.
But if you’re a clinician using etamsylate, it’s worth understanding the current limits of the evidence. The drug, at the standard veterinary dose given as a single IV injection, doesn’t produce detectable changes in coagulation parameters within 90 minutes. If your patient improves after receiving it, that improvement may be real, but the mechanism behind it is still poorly understood and may not relate to what we traditionally think of as “clotting.”
Study limitations worth knowing
The Munich team is straightforward about the constraints of their work. The patient population was intentionally heterogeneous, which is good for generalizability but bad for detecting subtle effects in any one category. The single time point (90 minutes) might have missed the drug’s window of action. Fibrinogen data were missing for 8 of 30 dogs due to lab errors, which trimmed the statistical power for that variable.
Despite these issues, the study followed standardized TEG protocols, used appropriate corrections for multiple testing, and enrolled enough animals to detect a 30% change in MA with 80% power. If etamsylate had a meaningful effect on the parameters measured, this study should have found it.
Where research should go next
The authors suggest a few productive directions. Tests that incorporate vascular endothelial function, such as mucosal bleeding time or platelet adhesion assays, would better capture whatever etamsylate might be doing at the vessel wall. Dose-ranging studies would clarify whether higher or more frequent dosing produces measurable changes. And focusing on a single, more uniform patient group, rather than mixing surgical, traumatic, and thrombocytopenic cases, would make it easier to detect effects specific to each scenario.
We know etamsylate is safe. What we don’t know, even after this study, is exactly what it’s doing in the body. That gap deserves to be closed.
Frequently Asked Questions
Is etamsylate the same as tranexamic acid?
No. Tranexamic acid is an antifibrinolytic, meaning it stops clots from breaking down once they’ve formed. Etamsylate targets an earlier step in the process and is thought to work by activating platelets and reducing capillary fragility. They belong to different drug classes and operate through different mechanisms.
Is etamsylate safe?
Based on current evidence, yes. The Munich study found no adverse events across 30 dogs, and earlier research has shown tolerability at doses far above the standard clinical amount (up to 200 mg/kg in dogs). In human medicine, the drug has been in use since 1959 without major safety concerns emerging.
Does etamsylate actually stop bleeding?
That depends on what you measure. Clinical observations suggest it helps in some situations, such as hemorrhagic diarrhea in dogs and perioperative bleeding in humans. But when researchers measure coagulation parameters directly using thromboelastography and standard clotting tests, the drug produces no statistically significant changes at the standard veterinary dose.
Why didn’t the Munich study find any effect?
There are several possible reasons. The drug may work through vascular endothelium mechanisms that blood tests in a cup simply can’t detect. The dose (12.5 mg/kg as a single injection) might be too low or given too infrequently. The 90-minute sampling window might have missed peak activity. In vitro studies do show effects, but only at much higher concentrations than those achievable with a standard clinical dose.
What is thromboelastography (TEG)?
TEG is a test that measures how a blood clot forms and dissolves in real time. A small sample of blood goes into a rotating cup with a pin suspended in it. As the blood clots, the pin moves with the cup, and sensors track parameters like reaction time, clot speed, maximum strength, and dissolution rate. It gives a more complete picture of hemostasis than individual lab tests like PT or aPTT.
Should veterinarians stop using etamsylate?
Not necessarily. The drug is safe, and some clinical evidence still supports its use. What the study suggests is that clinicians should be realistic about the current evidence gap. If a patient improves after receiving etamsylate, the improvement may be real, but the mechanism behind it is not well characterized by existing diagnostic tools.
Was this study done in humans?
No. The Munich study was conducted on dogs. However, previous research in humans and pigs has also found no measurable impact of etamsylate on standard coagulation parameters, so the findings are consistent across species.
What dose of etamsylate was used in the study?
12.5 mg/kg, given as a single intravenous injection. This is the standard veterinary dose in many countries. Blood samples were collected 90 minutes after administration.
